Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Soleno Therapeutics Q2 EPS $(0.57) Beats $(0.63) Estimate

Author: Benzinga Newsdesk | August 07, 2024 04:34pm
Soleno Therapeutics (NASDAQ:SLNO) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.63) by 9.52 percent. This is a 29.63 percent increase over losses of $(0.81) per share from the same period last year.

Posted In: SLNO

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist